Denali Advisors LLC Lowers Stock Position in DaVita Inc. $DVA

by · The Markets Daily

Denali Advisors LLC decreased its holdings in DaVita Inc. (NYSE:DVA – Free Report) by 55.2% in the 2nd quarter, Holdings Channel reports. The firm owned 2,528 shares of the company’s stock after selling 3,113 shares during the period. Denali Advisors LLC’s holdings in DaVita were worth $562,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also recently bought and sold shares of the business. Value Investment Professionals LLC grew its position in DaVita by 2.0% during the 2nd quarter. Value Investment Professionals LLC now owns 2,501 shares of the company’s stock worth $556,000 after purchasing an additional 50 shares during the last quarter. Kesler Norman & Wride LLC raised its holdings in shares of DaVita by 0.8% in the first quarter. Kesler Norman & Wride LLC now owns 6,816 shares of the company’s stock valued at $1,048,000 after buying an additional 55 shares during the last quarter. Gen Wealth Partners Inc boosted its stake in shares of DaVita by 10.0% during the fourth quarter. Gen Wealth Partners Inc now owns 880 shares of the company’s stock worth $100,000 after buying an additional 80 shares during the period. NewEdge Advisors LLC grew its holdings in shares of DaVita by 20.8% during the first quarter. NewEdge Advisors LLC now owns 511 shares of the company’s stock worth $78,000 after buying an additional 88 shares during the last quarter. Finally, Orion Porfolio Solutions LLC increased its position in DaVita by 4.4% in the 4th quarter. Orion Porfolio Solutions LLC now owns 2,360 shares of the company’s stock valued at $268,000 after acquiring an additional 99 shares during the period. Institutional investors and hedge funds own 90.12% of the company’s stock.

Analyst Ratings Changes

DVA has been the subject of several analyst reports. UBS Group upped their price objective on DaVita from $235.00 to $270.00 and gave the company a “buy” rating in a research note on Friday, July 10th. Oppenheimer set a $220.00 target price on DaVita in a research note on Friday, August 7th. Weiss Ratings upgraded DaVita from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, August 5th. Barclays increased their price target on DaVita from $218.00 to $224.00 and gave the stock an “equal weight” rating in a report on Wednesday, August 5th. Finally, Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and issued a $265.00 price objective on shares of DaVita in a research report on Wednesday, August 5th. Four research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $221.75.

View Our Latest Stock Analysis on DaVita

Insider Buying and Selling at DaVita

In related news, insider Kathleen Alyce Waters sold 15,405 shares of the company’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $208.40, for a total transaction of $3,210,402.00. Following the transaction, the insider owned 109,194 shares of the company’s stock, valued at $22,756,029.60. This represents a 12.36% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 1.90% of the stock is currently owned by company insiders.

DaVita Stock Down 1.0%

Shares of NYSE:DVA opened at $175.54 on Friday. The company has a market cap of $11.20 billion, a P/E ratio of 14.36, a PEG ratio of 0.59 and a beta of 0.88. DaVita Inc. has a 52 week low of $101.00 and a 52 week high of $247.49. The company has a 50-day moving average price of $215.64 and a 200 day moving average price of $181.58.

DaVita (NYSE:DVA – Get Free Report) last released its earnings results on Tuesday, August 4th. The company reported $4.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.88 by $0.14. The company had revenue of $3.55 billion for the quarter, compared to analysts’ expectations of $3.50 billion. DaVita had a negative return on equity of 217.63% and a net margin of 6.05%.The firm’s quarterly revenue was up 5.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.95 EPS. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. Analysts expect that DaVita Inc. will post 14.57 EPS for the current year.

DaVita Company Profile

(Free Report)

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.

Further Reading

Want to see what other hedge funds are holding DVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DaVita Inc. (NYSE:DVA – Free Report).